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Validation of the patient activation measure in a multiple sclerosis clinic
sample and implications for care
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1

Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA, USA, 2Department of Planning,
Public Policy and Management, University of Oregon, Portland, OR, USA, 3School of Medicine, Medical College of Georgia,
Augusta, GA, USA, 4Charlie Norwood Veterans Affairs Medical Center, Augusta, GA, USA, and 5Neuroscience Associates
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Abstract
Purpose. Patient engagement in multiple sclerosis (MS) care can be challenging at times given the unpredictable disease
course, wide range of symptoms, variable therapeutic response to treatment and high rates of patient depression. Patient
activation, a model for conceptualising patients’ involvement in their health care, has been found useful for discerning
patient differences in chronic illness management. The purpose of this study was to validate the patient activation measure
(PAM-13) in an MS clinic sample.
Methods. This was a survey study of 199 MS clinic patients. Participants completed the PAM-13 along with measures of
MS medication adherence, self-efficacy, depression and quality of life.
Results. Results from Rasch and correlation analyses indicate that the PAM-13 is reliable and valid for the MS population.
Activation was associated with MS self-efficacy, depression and quality of life but not with self-reported medication
adherence. Also, participants with relapse-remitting MS, current employment, or high levels of education were more
activated than other subgroups.
Conclusions. The PAM-13 is a useful tool for understanding health behaviours in MS. The findings of this study support
further clinical consideration and investigation into developing interventions to increase patient activation and improve
health outcomes in MS.
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Introduction
Engaging patients in health behaviours related to the
management of chronic illness is a challenging
endeavour for healthcare professionals. Although
treatment adherence is difficult in many chronic
conditions, the need for regular self-injections or
hospital based infusions and the side effects of these
disease modifying therapies (DMT), such as fever,
chills, sweating, muscle aches and fatigue, can be
especially trying in multiple sclerosis (MS) [1].
Although these treatments have been found to
decrease the frequency of exacerbation, disability
progression, and demylination, outcomes vary

widely. Treatment failure is not uncommon, which
further complicates care [2]. Given that DMT are
frequently not the only therapeutic intervention
employed, patients also must contend with the
complexities associated with managing secondary
symptoms, such as fatigue, pain, depression and
urinary and bowel incontinence [3,4].
In addition to the difficulties pertaining directly to
the treatment itself, certain psychosocial factors have
been shown to predict how well a patient will comply
with DMT. Patients’ perceptions of how a treatment
is working [5], their sense of MS-related self-efficacy
(i.e., confidence that one can administer self-injections), anxiety about self-injections [6] and whether
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or not a patient believes that the injections are
actually beneficial [7] also have been strongly related
to whether or not they continue the treatment.
Patient activation
One construct that has proven useful when considering patient commitment and follow-through
with treatment is patient activation, which has been
used to describe patients’ degree of engagement in
their health care. Components of patient activation
include one’s knowledge about his/her health condition, perceived ability to follow through with treatment, and comfort collaborating with and being able
to express concerns to health care providers [8].
Hibbard et al. [8] conceptualise patient activation
as a developmental patient process of four progressive levels. At the lowest level, patients tend to be
overwhelmed with the task of managing their health
and may not feel ready to take an active role. At level
two, patients realise that they have a role to play in
their health care, but may lack the knowledge and
confidence to manage their health. At level three,
patients are beginning to take action, but may still
lack some confidence to manage all aspects of their
health. At level four, patients struggle with being able
to maintain the behaviours they have already
adopted.
Because highly activated patients assess their role
in the management of their conditions as very
important, they will pursue and strive to access the
best health care available. Alternatively, patients with
lower activation are less likely to carry out selfmanagement behaviours and adhere to medications
[8,9]. Higher levels of patient activation have been
associated with better health overall [10] and have
also been shown to predict a number of specific
health-related outcomes among people with chronic
disease, such as hypertension control in diabetics
[11] and pain management in patients with chronic
kidney disease [12]. It appears that patients who
actively participate in their care may be better able to
provide doctors with valuable information needed for
diagnosis and treatment [13], which in turn can
result in more informed and supportive providers
and improved health outcomes [14,15].
Researchers have also begun to examine to what
extent patient activation can be modified. One
intervention designed to raise patient activation
levels in individuals with diabetes was found to
increase the number of questions that patients asked
of their clinicians. Moreover, these patients reported
fewer physical limitations at a 4-month follow-up
[16]. Hibbard et al. [10] conducted an intervention
with patients with chronic disease to determine
whether changes in activation were accompanied by
changes in health behaviour, concluding that a

variety of health behaviours improved when activation increased, such as engaging regularly in exercise,
managing stress, paying attention to amount of fat in
diet, and taking diabetes medication as recommended. In another study of patients with chronic
conditions, those with higher patient activation were
more likely to perform self-management tasks, use
self-management services, and report high levels of
medication adherence [9].
Patient activation may be especially important in
chronic illnesses like MS, because fluctuating physical circumstances require patients to stay involved
and continually make new decisions regarding their
care [17]. As DMT are often begun early in MS
disease course, it is important that even newly
diagnosed patients begin to appreciate their role in
the management of symptoms [2]. Increasing patient
knowledge about the condition and available treatments is key, as unrealistic expectations of MS
treatments and insufficient or inaccurate knowledge
about medications affect levels of compliance
[1,18,19]. Likewise, improved health care communication could help patients more readily express
their concerns about self-injection [18], treatment
side effects, and frequently unaddressed issues like
sexual dysfunction to improve education and early
intervention efforts. Additionally, fatigue in MS
impacts communication [20] and therefore communication is of primordial importance for patients with
MS.
Another component of patient activation is selfefficacy, which is a person’s belief that they can
overcome particular challenges and carry out a
course of action [21]. According to one study, selfefficacy was found to be a major predictor of
adjustment to having MS [22] and also predicted
self-worth after diagnosis [23]. Another study reported that low self-injection self-efficacy, was
related to patient expectation of having major
difficulties or a complete inability to self-inject [6].
Self-efficacy training has been shown to increase
exercise adherence in MS patients [21]. Further,
involving MS patients in counselling to identify
treatment related problems, create goals, and develop intervention strategies increased MS self-efficacy
ratings [24].
Because self-efficacy in MS patients has been
shown to be lower in patients with depression and/or
anxiety [25], these individuals may be especially at
risk for having low activation levels. It is estimated
that lifetime rates of major depression are as high as
50% after diagnosis [26] and that MS patients have
higher rates of depression than in many other chronic
illnesses, including other neurological illnesses
[27,28]. Depression can negatively impact levels of
patient activation, as depression leads to loss of
incentive and increased participation in avoidance

behaviours that can directly affect a patient’s level of
functioning [29] and affect quality of life [30]. In the
MS population, it has been shown that higher rates
of depression are associated with avoidance strategies
and that lower rates of depression are associated with
patients acquiring new strategies for problem solving
[31,32]. Thus, treatment of depression is vital, as
decreasing depressive symptoms could assist in
increasing activation.

The patient activation measure
One psychometrically sound instrument that has
been used to assess patient activation is the patient
activation measure (PAM), a unidimensional scale
reflecting Hibbard et al.’s [8] developmental model
of activation. The PAM is a self-report measure
designed to assess a patients’ knowledge, skill and
confidence in managing their health or chronic
condition [8]. The 22 item PAM was developed
using Rasch modelling, a measurement method
which has gained popularity, in part, because of its
ability to assess constructs with fewer items and thus
lessen patient questionnaire burden [33]. Rasch
models are based on item-response theory as a
method of describing latent traits (abilities or
attitudes) [34] and can produce interval-level, unidimensional and probabilistic Guttman-type scales
from ordinal data [10]. Participants are located on
the measurement scale from least to most of the
assessed ability (in this case activation) while items
are located on the same scale from least difficult to
most difficult. Although located on the same scale,
item and person measures are statistically independent of each other, enabling the calibration of item
difficulty to be independent of the ability level of the
respondent. Information weighted fit (INFIT) and
outlier-sensitive fit (OUTFIT) mean squares are
calculated to determine the goodness of fit to the
Rasch model, with most studies utilising a range of
0.70–1.30 as acceptable fit with 1.00 indicating
perfect fit [33]. Finally, the standard error of
measurement represents the precision with which
an item’s or individual’s scale location has been
estimated [8].
The PAM was initially validated on a randomly
selected national probability sample of 1515 participants 45 years or older [8], but has since been
utilised with other populations, including persons
with chronic illness (e.g, diabetes, arthritis, hypertension, heart disease, chronic obstructive pulmonary
disease and hyperlipidemia) and persons undergoing
spinal surgery [9,35]. The initial PAM study
demonstrated good psychometric properties including a high Rasch person reliability statistic with
INFIT values ranging from 0.71 to 1.44 and all but

one of the OUTFIT statistics ranging between 0.80
and 1.34 [8]. A short form of the PAM (PAM-13)
was developed and validated from the original
sample and yielded similar psychometric properties
to the 22-item version, with lower, but acceptable,
reliability and INFIT and OUTFIT statistics falling
within a range of 0.50–1.50 [36].
Though the PAM has been utilised in other
chronic illness populations, it has not been validated
on the MS population. Although MS shares similarities to other chronic illness groups, it is also unique
in that a majority of individuals experience an
unpredictable relapse-remitting disease course and
receive DMT with widely varied outcomes. This
could alter how ‘in control’ individuals living with
MS feel with regard to their illness and hence how
activated they might be. If the PAM were demonstrated to be a valuable tool for MS patients, it could
help identify those who may benefit from increased
patient activation through therapeutic, educational,
and supportive interventions targeting factors affecting MS patients’ ability to engage more fully in care.
Thus, the purpose of this study is to evaluate the
validity of the PAM in an MS clinic sample.

Method
Participants
A sample of 199 respondents was recruited from a
regional Multiple Sclerosis Centre affiliated with an
academic medical centre in the southeastern United
States. Most participants were female (n ¼ 163,
82%), married (n ¼ 120, 60%) and Caucasian
(n ¼ 137, 68.8%), with a mean age at the time of
the study of 46.24 (SD ¼ 10.83), and their average
years since diagnosis was 8.30 (SD ¼ 6.84). Educational level varied, with 45 (22%) having earned a
GED/High School diploma, 49 (24%) having some
college education, 32 (16%) earning an associate’s
degree, and 16% a bachelor’s degree (see Table I).
Half were unemployed (n ¼ 109), 29.6% were
employed full time (n ¼ 59), and 42% received
disability benefits for MS (n ¼ 83). Sixty-six
percent of participants had relapse-remitting MS
(n ¼ 131).

Measures
A demographic survey collected information on age,
gender, ethnicity, years of education, employment/
disability status, and marital status. A second part of
this survey collected specifics about MS disease,
including MS subtype, years and months since MS
diagnosis, and self-reported medication adherence.

Table I. Demographics of the MS clinic sample.
M (SD)
Sample
Female
Current age
Years since diagnosis
Race
Native American
African-American
Hispanic/Latino
Caucasian
Biracial
Marital status
Single/never married
Married
Living with partner
Separated
Divorced
Widowed
Education
Some high school
GED/HS diploma
Some college
2-year college/
Associate’s degree
4-year college/
Bachelor’s degree
Master’s
Doctoral/PhD
Professional degree (MD, JD)
Employment status
Full time
Part time
Unemployed
Retired
Disability
Type of MS
Relapse-remitting
Progressive
Secondary progressive
Unsure

n

%

199
163

100.00
81.90

1
54
2
137
4

0.50
27.10
1.00
68.80
2.00

30
120
3
7
34
5

15.10
60.30
1.50
3.50
17.10
2.50

9
45
49
32

4.50
22.70
24.70
16.20

32

16.10

23
2
6

11.60
1.00
3.00

59
14
109
10
3

30.30
7.20
55.90
5.10
1.50

131
8
15
37

68.60
4.20
7.90
19.40

46.24 (10.83)
8.30 (6.84)

Adherence was measured using a single item in
which patients responded to the frequency at which
they missed doses of their DMT. Respondents also
completed the PAM-13, along with measures of
depression, MS self-efficacy, and quality of life to
establish convergent and discriminant validity.
The PAM-13 [36] is the short form of the 22-item
PAM developed by Hibbard et al. [8] and measures
patient knowledge, skill, and confidence for medical
self-management. Individuals respond to items such
as ‘I know how to prevent further problems with my
health condition’, using a scale ranging from
‘strongly disagree’ to ‘strongly agree’. The PAM-13
is scored on a scale from 0 to 100 indicating strength
of agreement, with larger numbers indicating greater
agreement with the item. An average score of the 13
item responses is obtained with higher total scores
equalling higher activation. The PAM-13 has similar
psychometric properties to the original 22 item

measure [36], with INFIT and OUTFIT statistics
for each item ranging from 0.50 to 1.50. Cronbach’s
a was .88 for this sample.
The Beck depression inventory (BDI-II) [37] is a
21 item, multiple-choice, self-report measure of
depression with affective (8 items) and somatic (13
items) subscales. Responses to each item range
from 0 to 3, with higher scores reflecting more
severe symptomatology. Total scale scores of 0–13
are considered in the minimal range, 14–19 are
mild, 20–28 are moderate, and 29–63 are indicative of severe depression. The BDI-II has strong
reliability in the current sample (a ¼ 0.92) and
has been used in treatment studies with MS
samples [6].
The multiple sclerosis self-efficacy scale (MSSE) [38],
is an 18-item scale divided into two subscales:
function and control. The items aim at assessing
how confident individuals feel that they can achieve
specific functions (e.g., ‘As of now, how certain are
you that you can walk 100 feet on flat ground’?) or
control various aspects of their MS (e.g., ‘As of now,
how certain are you that you can control your
fatigue’?). Responses are rated on a 100-point
continuum, from 10 to 100 in 10-point increments,
with higher scores associated with higher degrees of
certainty. Scores are totalled on each subscale
(function and control) and a total MMSE score is
obtained as well. The MSSE has been found to have
high internal consistency and test–retest reliability
[38]. The Cronbach’s a in this sample was high
(a ¼ 0.96) for the total scale.
Leeds multiple sclerosis quality of life (MSQOL) [39]
is an 8-item self-report scale assessing well-being in
patients with MS in the last month. Items like, ‘My
health has affected my relationships with my family’
are rated on a 0–3 point scale (0 ¼ ‘not at all’ to
3 ¼ ‘very much’). The total scale score ranges from 0
to 24, with higher scores indicating higher wellbeing. The scale demonstrated acceptable reliability
(a ¼ 0.79) [39]. The reliability coefficient in this
sample was 0.80.

Procedures
The data was collected in conjunction with patients’
routine MS Centre visits. Adult patients with
definitive MS and limited cognitive impairment,
per neurologist assessment, were deemed eligible for
participation. Patients were queried during their visit
regarding voluntary study participation and those
interested were provided with verbal and written
informed consent. Survey packets took approximately 25 min to complete and patients received
no remuneration for participation. Assistance with
completion due to MS symptoms (reading or

marking items) was provided at MS patient request.
Institutional Review Board approval was received
prior to study initiation.

Results
Data was reviewed for completeness prior to statistical
computation. For patients with less than 10% of their
data missing on any given questionnaire, a respondent-specific mean score was computed from the
completed items and imputed. Individual questionnaires with more than 10% of the data missing were
eliminated prior to the specific analysis utilising that
data. Missing data appeared to be randomly distributed across the survey instruments.
Patient activation measure scores for this sample
ranged from 36.07 to 99.97 with a mean of 63.18
(SD ¼ 11.87). We used Hibbard’s scoring [9] to
determine individuals’ level of patient activation.
The PAM scores of 14 participants (7.1%) were
under 47, indicating level 1 of patient activation (not
understanding an active role is important). Thirtyseven participants (18.9%) scored between 47.1 and
55.2 on the PAM, indicating level 2 of patient
activation (lacks knowledge and confidence to take
action). The majority (n ¼ 78, 39.8%) scored between 55.2 and 67.0 on the PAM, indicating level 3
of patient activation (beginning to take action).
Finally, 67 participants (34.2%) scored above 67.1
on the PAM indicating a level 4 level of patient
activation (maintaining behaviours over time). These
results are on par with Hibbard and Cummingham’s
[40] findings of activation levels for patients with
chronic conditions. One exception was that our
sample seemed to have a higher percentage of
patients in level three and a lower percentage in
level four as compared to the mean percentages
among those with chronic conditions in Hibbard and
Cunningham’s work [40] as seen in Table II.

PAM-13 fit in MS
The PAM-13 was assessed for unidimensionality and
item fit using the Winsteps Rasch modelling software
application [41]. The PAM-13 showed good reliability (Rasch person reliability ¼ 0.83 and Rasch item
reliability ¼ 0.98) and unidimensionality (a ¼ 0.88).
The high reliability coefficients indicate that the
measure is appropriate for individual-level use.
The fit of the individual items was evaluated using
the Rasch analysis model. The fit of each item to the
Rasch model is assessed by the information weighted
mean-square residual goodness of fit statistics INFIT
and OUTFIT] [42]. An INFIT/OUTFIT valued of
50.7 indicates that the item does not provide any
more information than the rest of the items on the
scale, possibly because items are similar or highly
correlated. An INFIT/OUTFIT value 41.3 indicates that the item is either poorly constructed,
ambiguously defined, or does not define the same
construct as the rest of the items. An acceptable range
for an INFIT/OUTFIT value is usually between 0.7
and 1.3 [43]. For our sample, The PAM-13 INFIT/
OUTFIT values range 0.76 and 1.15, for 12 out of
the 13 items, well within the range required for a
unidimensional measure. Only one item (Item 1 –
‘When all is said and done, I am the person who is
responsible for taking care of my health problems’)
had an INFIT value of 1.57, indicating a possible
lack of fit with the model. The INFIT/OUTFIT
statistics are presented in Table III.

PAM-13 and relationships to other variables
As expected, the PAM was most strongly positively
correlated to total MSSE (r ¼ 0.50, p 5 0.01),
indicating patients with higher activation had higher
MS self-efficacy. Because self-efficacy is part of the
patient activation construct, it was expected that this

Table II. Comparison of MS patient activation levels with Hibbard & Cunningham chronic medical condition groups [37].
Level of activation

All persons with chronic
conditions [40]
Selected conditions
Diabetes
Arthritis
Asthma
Hypertension
Heart disease
Cancer
Depression
MS sample

Level 1
(least activated)

Level 2

Level 3

Level 4
(most activated)

Overall activation
score (adjusted)

8.6%

17.3%

33.9%

40.1%

64.2

18.9
19.1
16.8
18.5
18.9
12.2
21.1
18.9

35.3
32.2
32.5
34.2
34.0
34.5
29.4
39.8

37.9
37.5
42.7
37.7
35.5
45.5
36.8
34.2

65.3
63.2
64.8
63.5
64.0
65.8
62.1
63.2

7.9
11.2
8.1
9.6
11.6
7.8
12.6
7.1

Table III. PAM-13 with item calibration for MS population.

1. When all is said and done, I am the person who is
responsible for taking care of my health problem
2. Taking an active role in my own health care is the most
important thing that affects my health
3. I am confident I can help prevent or reduce the
problems associated with my health condition
4. I know what each of my prescribed medications does
5. I am confident I can tell whether I need to go to the
doctor or whether I can take care of a health problem
myself
6. I am confident that I can tell a doctor my concerns I
have even when he or she does not ask
7. I am confident I can follow through on medical
treatments I need to do at home
8. I understand my health problems and what causes them
9. I know what treatments are available for my health
problems
10. I have been able to maintain (keep up with) lifestyle
changes, like eating right or exercising
11. I know how to prevent further problems with my health
condition
12. I am confident I can figure out solutions when new
problems arise with my health condition
13. I am confident that I can maintain lifestyle changes like
diet and exercise even during times of stress

Measure*

SEM{

INFIT{

OUTFITx

41.73

1.06

1.57

1.79

39.47

1.10

0.93

0.86

51.13

0.96

0.92

0.89

43.33
46.64

1.05
1.00

1.12
1.10

1.03
1.07

39.13

1.10

0.76

0.66

38.98

1.11

0.76

0.73

45.00
46.48

1.02
0.99

1.06
0.98

0.97
1.15

58.65

0.90

1.1

1.14

58.13

0.91

0.79

0.79

58.55

0.90

0.92

0.92

59.94

0.89

1.13

1.15

*The calibrated scale value of the item is how much activation is required to endorse this item.
{
The standard error of measurement is precision of the item difficulty estimation.
{
INFIT is an information-weighted residual of the observed responses from the model expected responses. INFIT mean square error is a
quality control fit statistics assessing item dimensionality.
x
OUTFIT mean square error fit statistic is sensitive to unexpected observations made by respondents on items that would be either very easy
or very hard for them. It is an outlier-sensitive statistic.

association would be strong due to the construct
overlap, but still remain conceptually distinct. Significant correlation between the PAM-13 and the
BDI-II (r ¼ 70.43, p 5 0.01) and MS QOL
(r ¼ 0.42, p 5 0.01) were also in the anticipated
direction, such that higher activation was associated
with lower depression and higher well-being. With
regard to adherence, self reported frequency of
missing DMT injections (for those on treatment)
unexpectedly was not correlated to patient activation
(r ¼ 70.04, p ¼ 0.57).

Between-group differences in the PAM-13
Three of the demographic variables were significantly correlated with patient activation scores
(employment status, education level, and type of
MS) and thus were subjected to further analysis. To
ensure adequate n within each group, the employment variable was collapsed into patients employed
at any level (full or part time) and patient not
currently employed (retirement, unemployment,
disabled). Similarly, patients with any type of
progressive MS (primary and secondary) were

grouped together as distinct from those with relapse-remitting MS. Three groups were created for
education: patients with a high school education and
below, patients with some college or a 2-year degree,
and patients with a 4-year degree and above.
Independent-samples t test were conducted with
the PAM for MS type and employment. The test
was significant for type of MS and the PAM,
t(149) ¼ 2.95, p 5 0.05. Patients with relapseremitting MS (M ¼ 42.29, SD ¼ 5.11) on average
had higher levels of patient activation than did
patients with a progressive MS (M ¼ 38.44, SD ¼
6.05). The t test was also significant for employment status and patient activation, t(190) ¼ 2.65,
p 5 0.05, such that those who were employed
had higher activation levels than those not employed.
A one-way ANOVA was conducted to evaluate the
relationship between education level and patient
activation. The ANOVA was significant, F(2,
192) ¼ 15.68, p 5 0.001. Follow-up tests were conducted to evaluate pairwise differences among the
means of the three groups. Because of sample
sizes differences, a Gabriel’s test was conducted.
Individuals with 4-year degrees and above (n ¼ 63)
had significantly higher activation scores (M ¼ 69.47,

Table IV. Correlations between PAM-13 and discriminant validity measures.
Total scores
PAM
MSQOL
BDI-II
MSSE-Full
MSSE-Fnct

r
N
r
N
r
N
r
N
r
N

PAM

MSQOL

BDI-II

MSSE-Full

MSSE-Fnct

MSSE-Control

(0.88)

0.42*
194
(0.80)

70.43*
187
70.72*
186
(0.92)

0.50*
189
0.62*
189
70.55*
184
(0.96)

0.41*
190
0.41*
190
70.38*
185
0.91*
190
(0.94)

0.49*
192
0.72*
192
70.63*
187
0.91*
191
0.68*
190
(0.96)

MSSE-Ctrl

Coefficient alpha estimates are listed on the main diagonal.
PAM, patient activation measure; MSQOL, multiple sclerosis quality of life; BDI-II, beck depression inventory-II; MSSE-full, multiple
sclerosis self-efficacy scale full; MSSE-Fnct, Multiple sclerosis self-efficacy scale function subscale; MSSE-Ctrl, Multiple sclerosis selfefficacy scale control subscale.
*Pearson correlation is significant at the 0.01 level (2-tailed).

SD ¼ 10.70) than individuals (n ¼ 80) with some
college or 2-year degrees (M ¼ 60.72, SD ¼ 11.85) or
individuals (n ¼ 52) with an educational level of high
school or below (M ¼ 59.08, SD ¼ 10.25). A significance level of p 5 0.001 in both comparisons was
obtained. The difference between the some college
or 2-year degrees group and the high school or below
group was not significant.

Discussion
The results indicate that the PAM-13 is both
reliable and valid for the MS population. The
Rasch model supported the use of the PAM-13 in
assessing patient activation in the MS population
overall, and findings were similar to those from
studies from the general population [36]. One
item, ‘When all is said and done, I am the person
who is responsible for taking care of my health
problems’ fell outside the range of usually acceptable fit statistics. Of all of the items in the
instrument, it is the one where responsibility for
health problem management falls most decisively
within the realm of the patient. Given unpredictability of MS relapse and the critical role that
health providers play in the management of
MS, especially within a multidisciplinary MS
Centre, patients with MS may respond slightly
differently than other populations to this item. This
may also account for why a smaller percentage of
MS patients were in the most activated category
when compared to other disease groups. Yet,
comparison of patient activation levels in this MS
sample with other chronic conditions support that
overall MS activation scores generally fall within
the range of those with other chronic medical
conditions.

PAM-13 scores did not correlate in this sample
with gender, race, or age, as they did in the original
PAM-13 study [36], but did correlate to employment status, education level, and MS subtype.
Follow-up tests supported mean differences of
activation using these demographic breakdowns,
with those having relapse and remitting MS, employment of some kind, or in the highest educational
group having higher activation scores than those
having progressive MS, no employment, or in the
lower educational groups. The current sample was
much smaller than national studies of the PAM and
may account for lack of significant findings within
some of the demographic subgroups. Similarly, due
to small sample size, the actual number of men and
minorities in the study were small. On the other
hand, 27.30% of the sample was African-American,
which is well above the proportion of AfricanAmericans in the US population in general. Additionally, when comparing our small and regionally
restricted sample to Slifka longitudinal MS data
(Minden, Frankel, Hadden, Perloff, Srinath, &
Hoaglin, 2006), our sample was on the whole similar
to the demographic characteristics of this national
sample of persons with MS. For example, compared
to the individuals in the Slifka study, participants in
the current study had a similar mean age (46.24 years
in our study compared to 50.70 years), were mostly
female (81.90% versus 77.00%), were married
(60.30% compared to 66.50%), and were in the
workforce (37.50% compared to 43.50%). In terms
of education, the samples did differ. Whereas
20.10% of participants in the current study were a
college graduate or had completed postgraduate
work, 40.10% were in the Slifka sample. The largest
relative difference was in ethnicity, as the Slifka
sample was 4.80% African-American versus 27.30%
in the current study. We view this as a distinct

strength of this investigation, given how few MS
studies have sizable African-American samples.
Activation levels were strongly correlated as anticipated to measures of MS self-efficacy, depression,
and quality of life. Given that this study does not
allow for examination of causal relationships, we do
not know whether activation drives depression, MS
self-efficacy, and quality of life, the other way around,
or another, more complex relationship. Despite this,
it is reasonable to consider addressing depression
with MS patients as a way to increase activation,
especially since as many as 25% of MS patients have
untreated or undiagnosed depression [45]. Moreover, there is good evidence that both antidepressants
[46] and psychotherapy [47] can improve and often
alleviate depressive symptoms in MS.
Similarly, it may be worthwhile pursuing interventions focused on improving MS self-efficacy in order
to increase activation. In one promising study, an 8week multidisciplinary health promotion class was
used as an intervention to increase MS patients’
knowledge, skills, and confidence for health promotion activities [48]. At the end of treatment, the
treatment group was found to have undertaken more
health promotion activities and had more health
promotion self-efficacy that did controls, and were
higher on some quality of life indicators, even at 3
months post-treatment. In terms of other patient
activation components, health literacy and patientphysician communication interventions should also
be pursued further with the MS population. Interestingly, one recent study found that among several
acute and chronic illness subgroups, there was no
difference in desire for participation in health care,
except for the MS group, which has significantly
higher participation preferences than all other
diagnostic groups [49].
Self-reported adherence to injection DMT was not
related to patient activation in this study. As
adherence was measured by a single item and the
sample size was not large, measurement and power
issues may have a role in these findings. Additionally,
our sample was skewed such that few patients
endorsed missing their medications in the upper
frequency range, with ‘somewhat often’ or ‘very
often’ representing 57% of the total sample, while
over 73% of the sample being at levels 3 or 4 with
regard to patient activation. It is also possible that
many patients with chronic adherence issues were no
longer on DMT and thus would have left that item
blank altogether. Given that difficulty adhering to
DMT is a well-documented issue for some individuals with MS [50] and patient activation has been
related to medication adherence in other populations
[9], it is prudent to consider additional, more
sophisticated exploration of these variables in future
studies.

The practical implication for this research is that
the PAM enables the assessment of patient activation
levels, which can be useful in informing clinical
practice. Understanding patients’ activation levels
may help improve medical care by allowing health
care providers to tailor their interactions and treatment according to the degree to which patients are
ready to assume responsibility for their care.
Patients’ level of activation also may prove to be a
useful gauge for likelihood of patients to follow
though and comply with treatment, especially in the
absence of family members and other caregivers to
assist. Given the chronic nature of MS and the
demanding treatment, understanding patients’ level
of activation may be crucial in identifying poor selfmanagement groups and seeking to address their
needs through supportive interventions. It is not yet
clear what contributes to patient activation nor what
type of intervention can increase it [8]. Future
research should focus on interventions to increase
activation in order to improve health care outcomes
and utilise the PAM as a starting point.

Limitations
The study findings have some generalisability limitations, given the restricted geographic region and lack
of men and minorities (other than African-Americans) in the sample. Given that women are disproportionately affected by MS, much larger samples
are often needed to be able to draw conclusions about
men when using a convenience sampling method.
Additionally, the correlational nature of the study
prevents us from making any causative conclusions
about the directionality of the relationships between
the PAM-13 and the other variables assessed.
Another limitation is our use of self-report instruments and lack of corroboration with physician report
and clinical findings. While future research should
seek to incorporate this data, there is evidence that for
some variables, like depression, a high degree of
overlap exists between patient self-report and physician ratings [26]. Despite the limitations, this study
provides many robust findings about patient activation in the MS population and can serve as a
springboard to future work in this area.

Conclusion
In conclusion, the PAM-13 appears to be valid in the
MS population and is related as anticipated to
depression, MS self-efficacy, and quality of life.
The PAM-13 can be used in the clinical setting as
well as in research as a more general measure
of patient engagement to augment MS specific

measures of care. Future studies can be directed
towards developing interventions to increase activation and improve health outcomes in MS. Additional
understanding of individuals at risk for low activation
levels, especially among those with less education,
would be especially beneficial in the development of
targeted interventions for that MS sub-population.
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